| Category | Details |
| Definition | MS is a chronic autoimmune disease affecting the central nervous system, characterized by inflammation, demyelination, and neurodegeneration. |
| Global Epidemiology | Approximately 2.8 million people globally live with MS. |
| More common in women, with a 3:1 female-to-male ratio. | |
| Prevalence in Key Regions | United States: ~1 million affected (~309 per 100,000). Current prevalence: Estimates from the National Multiple Sclerosis Society and recent studies indicate that nearly 1 million people in the U.S. live with MS. This reflects increases over previous estimates due to better diagnostic methods and longer life expectancy for those with MS. Historical data: A 2010 study estimated a prevalence of 309.2 per 100,000, equating to ~727,000 cases, which aligns with prior data trends. Regional variability: Higher prevalence rates are observed in northern states compared to southern ones, influenced by geographic and demographic factors. |
| European Union: over 1 million people living with MS in Europe. Annual incidence: Approximately 4.3 cases per 100,000, with new diagnoses contributing to the growing prevalence. Regional variability: Prevalence rates range from 80–90 per 100,000 in southern regions to 120–149 per 100,000 in northern Europe. Epidemiological challenges: Variations in data collection methods and population demographics make comparisons difficult. | |
| Canada: Among the highest prevalence rates globally (Canada has one of the highest global prevalence rates of multiple sclerosis (MS), historically estimated at 290 cases per 100,000 in 2010-2011. Recent data indicate over 93,500 Canadians currently live with MS, and projections suggest this could rise to 430 per 100,000 by 2031, exceeding 133,000 cases. Prevalence varies by province, with Nova Scotia reporting particularly high rates. This growth is driven by improved diagnostics, increased awareness, and longer survival rates. These figures solidify Canada’s leadership in MS research and the urgent need for targeted healthcare strategies. | |
| Australia: 33,335 Australians are living with MS, translating to a prevalence rate of approximately 131.1 per 100,000. Southern states, such as Tasmania, report higher prevalence rates exceeding 200 per 100,000, compared to lower rates in northern regions. | |
| Caribbean: Estimated 20,000–25,000 individuals, reflecting unmet medical needs. | |
| Medicinal Cannabis Approvals | United States (FDA): No specific cannabinoid product approved for MS spasticity; ongoing research. |
| European Union (EMA): Nabiximols (Sativex) approved for spasticity in MS unresponsive to other treatments (2010). The approval was based on pivotal Phase III clinical trials demonstrating that Sativex significantly reduced spasticity compared to placebo. The trials showed statistically significant benefits in various efficacy endpoints, confirming its effectiveness as a treatment option for MS-related spasticity | |
| Canada: Nabiximols approved as an adjunct for adult MS spasticity (2012). | |
| Australia (TGA): Nabiximols approved for MS-related spasticity (2013). The approval was based on clinical trials demonstrating the efficacy and safety of nabiximols for managing spasticity in MS patients. The pivotal trial involved assessing symptom improvement using a numeric rating scale for spasticity, confirming its effectiveness as an adjunct therapy | |
| Israel: Medical cannabis authorized for treatment-resistant MS spasticity since 2013. | |
| South Africa: Approved CBD-based therapies in 2017 for MS-related symptoms. In July 2017, Cannabidiol (CBD) was included under Schedule 6 of the Medicines and Related Substances Act in South Africa. This regulation was proclaimed by the Minister of Health and indicates that CBD can be prescribed for certain medical conditions, including MS-related symptoms, although specific products and their indications may still be limited . | |
| Therapeutic Cannabinoids | CBD (Cannabidiol): Anti-inflammatory and neuroprotective; shown to reduce neuroinflammation via CB2 receptor pathways. |
| THC (Tetrahydrocannabinol): Effective for muscle spasticity and neuropathic pain, with psychoactive effects. | |
| THCV (Tetrahydrocannabivarin): Emerging evidence suggests benefits in reducing MS spasticity. | |
| CBG (Cannabigerol): Investigated for neuroprotection and anti-inflammatory effects in MS. In vitro studies have demonstrated that CBG reduces the expression of inducible nitric oxide synthase (iNOS) and decreases levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α). These actions suggest that CBG may help mitigate the inflammatory response seen in MS, potentially leading to improved outcomes for patients | |
| Mechanism of Action | Nabiximols (1:1 THC:CBD): Modulates CB1 and CB2 receptors, reducing spasticity and neuroinflammation. |
| CBD: Reduces oxidative stress and excitatory neurotransmitter release, providing neuroprotective benefits. | |
| Key Clinical Studies | Markova et al., 2019: Nabiximols significantly improved MS spasticity compared to placebo. The meta-analysis included seven studies with a total of 1,128 patients. It found that the responder rate (patients showing improvement) was significantly higher in the nabiximols group compared to the placebo group, with an odds ratio (OR) of 2.41 (95% CI: 1.39; 4.18). This indicates that patients receiving nabiximols were more likely to report improvements in their spasticity compared to those receiving a placebo. |
| De Blasiis et al., 2021: Improved walking and balance in MS patients with spasticity using nabiximols. The study utilized 3D gait analysis to objectively measure changes in walking and balance before and after treatment with nabiximols. Participants included individuals diagnosed with MS who had not achieved adequate symptom relief from conventional antispasticity medications. The findings indicated that nabiximols led to significant improvements in both walking and balance after a treatment period. Specifically:Patients demonstrated enhanced gait parameters, indicating better walking stability and coordination. Improvements were maintained over a four-week period, suggesting that the benefits of nabiximols extend beyond immediate effects. | |
| Conte et al., 2021: Comprehensive review confirmed nabiximols’ efficacy for moderate-to-severe spasticity. Initial responder rates (defined as a ≥20% improvement in NRS scores from baseline at week 4) ranged from 47.6% to 81.4%, indicating that a significant proportion of patients experienced early symptomatic relief. Clinically relevant responder rates (≥30% improvement at week 12) were consistent across study types, with rates ranging from 30% to 41%. | |
| Meuth et al., 2020: Substantial reduction in spasticity severity and duration with nabiximols. The findings demonstrated that patients treated with nabiximols experienced a significant reduction in spasticity severity compared to those receiving placebo. Specifically, the adjusted mean change on the NRS indicated a notable improvement in the nabiximols group. A substantial proportion of participants reported a reduction in the duration of spasticity episodes, contributing to improved overall function and quality of life. | |
| Dosage Guidelines | Nabiximols (Sativex): The maximum recommended dose of Sativex is 12 sprays per day. Each spray contains approximately 2.7 mg of THC and 2.5 mg of CBD. A titration period is necessary to find the optimal dose for each patient. This process typically spans up to 2 weeks, during which the dosage is gradually increased. Patients should leave at least 15 minutes between each spray to minimize the risk of adverse effects and ensure proper absorption. |
| Oral CBD: Start at 2.5 mg/kg/day; titrate based on therapeutic response. After one week on the initial dose, the dosage can be increased to 5 mg/kg twice daily, resulting in a total of 10 mg/kg/day. This titration allows for adjustments based on therapeutic response and tolerability. | |
| THC (Inhaled): Doses of 1–2 mg per session for spasticity relief; gradual titration to effect. | |
| CBG (Experimental): Preclinical doses range from 5–20 mg/day under investigation for neuroprotection. CBG has been investigated in various preclinical studies, with effective doses often falling within the range of 5 to 20 mg/day. For example, one study utilized a dose of 10 mg/kg in mice, which translates to approximately 50 mg/day for a typical adult mouse, indicating its potential efficacy at higher doses in animal models. | |
| Administration Methods | Sublingual Spray (Nabiximols): Direct absorption through mucosal membranes, ensuring rapid onset. The spray is designed for oromucosal use, meaning it is applied under the tongue or to the inner cheek, allowing cannabinoids to be absorbed directly into the bloodstream through the mucosal membranes. |
| Oral Capsules: Preferred for controlled dosing; slower onset (60–90 minutes). Oral capsules provide a pre-measured dose of THC, which allows for precise and consistent dosing. This is beneficial for patients who prefer to avoid the variability associated with vaping. | |
| Inhalation: Rarely used for MS due to dosing unpredictability; suitable for acute symptom relief. Despite the issues with dosing, inhalation is suitable for acute symptom relief. Patients may choose this method when immediate relief is needed, such as during a spasticity episode or severe pain flare-up. The onset of effects from inhaled THC is rapid, typically occurring within minutes, which can be beneficial for managing sudden symptoms. | |
| Adverse Effects | CBD: Mild effects like fatigue, diarrhea, and altered appetite; rare elevation in liver enzymes. |
| THC: Psychoactive effects include anxiety, dizziness, and memory impairment; long-term risks of dependence. | |
| Nabiximols: Common side effects include dry mouth, dizziness, and fatigue; rare cases of psychosis. | |
| Research Gaps | Lack of data on long-term safety and efficacy of minor cannabinoids (e.g., CBG, THCV) for MS. |
| Cannabinoid-drug interactions with disease-modifying MS therapies remain underexplored. Current literature indicates that there is a lack of comprehensive studies investigating how cannabinoids interact with various DMTs used in MS treatment. While some studies have identified potential interactions, the overall understanding of these interactions remains insufficient, particularly regarding their clinical implications. | |
| Opportunities in the Caribbean | Growing prevalence of MS: Estimated 20,000–25,000 cases across the region. |
| Cannabis Clinics: Specialized cannabis clinics could serve local populations and medical tourists seeking MS treatments. | |
| Regional Research Initiatives: Collaborative research could position the Caribbean as a leader in MS cannabinoid therapies. |
